Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
38 participants
INTERVENTIONAL
2017-05-15
2019-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transcranial Magnetic Stimulation in Substance Use Disorder Patients
NCT06066164
Brain Mechanism and Intervention of Executive-control Dysfunction Among Substance Dependents
NCT05312359
Targeting Auditory Hallucinations With Alternating Current Stimulation
NCT03221270
Identifying Electrophysiological Targets for Transcranial Magnetic Stimulation in Cocaine Use Disorder
NCT05986578
A Preliminary Investigation of Pre-Frontal Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Cannabis Use Disorder
NCT03144232
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active Sham (Session 1 and Session 2)
Active sham transcranial alternating current stimulation (tACS) during Session 1 and Session 2
Active sham transcranial alternating current stimulation
Active sham (placebo)
Active Sham (Session 1) and tACS at 10 Hz (Session 2)
Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 10 Hz during Session 2
Transcranial Alternating Current Stimulation at 10 Hz
Non-invasive, safe transcranial alternating current stimulation administered at 10 Hz to target alpha oscillatory activity
Active Sham (Session 1) and tACS at 40 Hz (Session 2)
Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 40 Hz during Session 2
Transcranial Alternating Current Stimulation at 40 Hz
Non-invasive, safe transcranial alternating current stimulation administered at 40 Hz to target gamma oscillatory activity
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcranial Alternating Current Stimulation at 10 Hz
Non-invasive, safe transcranial alternating current stimulation administered at 10 Hz to target alpha oscillatory activity
Transcranial Alternating Current Stimulation at 40 Hz
Non-invasive, safe transcranial alternating current stimulation administered at 40 Hz to target gamma oscillatory activity
Active sham transcranial alternating current stimulation
Active sham (placebo)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current smoker
* Abstinent from all substances (except nicotine) for at least the past 2 weeks
Exclusion Criteria
* Less than 6 months since an electroconvulsive therapy (ECT) session
* Current DSM-V Psychotic Disorder
* Pregnancy and/or nursing
* Ongoing or history of traumatic brain injury (TBI), reoccurring seizures, stroke, or brain tumors
* Medical or neurological illness
* Brain devices and/or implants
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of North Carolina, Chapel Hill
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stacey B Daughters, PhD
Role: PRINCIPAL_INVESTIGATOR
University of North Carolina, Chapel Hill
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Southlight Healthcare
Raleigh, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-2342
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.